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Abstract
Background: The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting b2-agonist
(LABA) formoterol fumarate (formoterol) are being made available as a combination product (fluticasone/
formoterol, flutiform
®) in a single aerosol inhaler. This 12-week, open-label, randomized, active-controlled, parallel-
group, multicentre, phase 3 study compared the efficacy and safety of fluticasone/formoterol with the
commercially available combination product fluticasone/salmeterol.
Methods: Patients aged ≥ 18 years (N = 202) with mild-to-moderate–severe, persistent asthma for ≥ 6 months
prior to screening were included in the study. After a screening phase (4–10 days), eligible patients were
randomized 1:1 to receive fluticasone/formoterol or fluticasone/salmeterol during the 12-week treatment period.
The primary objective was to demonstrate non-inferiority of fluticasone/formoterol versus fluticasone/salmeterol,
measured by pre-dose forced expiratory volume in the first second (FEV1), at week 12.
Results: Fluticasone/formoterol was comparable to fluticasone/salmeterol for the primary efficacy endpoint, mean
pre-dose FEV1 at week 12. The new combination was also comparable to fluticasone/salmeterol for change from
baseline to week 12 in pre-dose FEV1, change from pre-dose FEV1 at baseline to 2-hour post-dose FEV1 at week 12
and discontinuations due to lack of efficacy. Importantly, fluticasone/formoterol was superior to fluticasone/
salmeterol in time to onset of action throughout the duration of the study. The two treatments demonstrated
similar results for various other secondary efficacy parameters, including other lung function tests, patient-reported
outcomes, rescue medication use, asthma exacerbations and Asthma Quality of Life Questionnaire scores.
Fluticasone/formoterol was well tolerated and had a good safety profile that was similar to fluticasone/salmeterol.
Conclusions: The results of this study indicate that fluticasone/formoterol is as effective as fluticasone/salmeterol,
and has a more rapid onset of action, reflecting the faster bronchodilatory effects of formoterol compared with
those of salmeterol. If patients perceive the benefits of therapy with fluticasone/formoterol more rapidly than with
fluticasone/salmeterol, this could have a positive impact on preference and adherence.
Trial Registration: ClinicalTrials.gov: NCT00476073
* Correspondence: abodzentalukaszyk@gmail.com
1Department of Allergology and Internal Medicine, Medical University of
Białystok, Białystok, Poland
Full list of author information is available at the end of the article
Bodzenta-Lukaszyk et al. BMC Pulmonary Medicine 2011, 11:28
http://www.biomedcentral.com/1471-2466/11/28
© 2011 Bodzenta-Lukaszyk et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Background
Asthma is one of the most common chronic diseases,
affecting an estimated 300 million people worldwide. Its
prevalence continues to rise in parallel with the increas-
ing urbanization of communities around the world, and
an estimated 100 million more people may be affected by
2025 [1]. At an individual level, asthma can have a con-
siderable impact on the quality of life of both patients
with asthma and their caregivers [2]. The vast economic
burden of asthma comprises both direct costs, such as
emergency care, hospitalizations and medications, and
indirect costs, largely driven by absenteeism and reduced
productivity [3]. In many regions, asthma-associated
mortality has declined in recent years, in line with
improved management strategies. Despite this, it is esti-
mated that asthma still accounts for approximately 1 in
250 deaths worldwide [1].
Recent data from Europe suggest that over 50% of
patients have asthma that is not well controlled [4]. This
is largely due to suboptimal use of their medication [5].
It has been suggested that inadequate levels of asthma
control account for over half of the existing economic
cost of the disease [6,7]. Furthermore, patient and physi-
cian perceptions of treatment effectiveness in practice
may be inaccurate. The International Asthma Patient
Insight Research (INSPIRE) study revealed that 87% of
patients with asthma that was not well controlled
classed their asthma control as relatively good [8].
Coupled with inaccuracies in physicians’ assessments of
their patients’ asthma control levels [9], these miscon-
ceptions probably contribute to the poor adherence of
patients to asthma therapy [10].
I fa d h e r e n c et oa s t h m at h e r a p yr e g i m e n si st ob e
improved, it is important to consider not only the efficacy
of treatment but also patients’ acceptance of it. There is
evidence to suggest that concurrent administration of
inhaled corticosteroids (ICSs) and long-acting b2-agonists
(LABAs) results in a synergistic interaction [11]. In addi-
tion, use of only a single inhaler to administer both drugs
is likely to improve patient adherence compared with
regimens involving treatments administered separately
[11,12]. While the benefits of ICS/LABA combination
therapies are well established, it is also important to con-
sider the specific components of the combination in
order to optimize levels of patient acceptance. The anti-
inflammatory effects of the ICS fluticasone propionate
(fluticasone) are rapid and sustained [13,14]. Fluticasone
is available in a single inhaler with salmeterol (flutica-
sone/salmeterol), which has proven clinical effectiveness
[15]. However, formoterol fumarate (formoterol), as the
most rapidly acting LABA (similar time to onset of action
to salbutamol [16]), is the bronchodilator of choice for
more recently available combination products with bude-
sonide and beclometasone.
Formoterol is now being made available with flutica-
sone in a single aerosol inhaler (fluticasone/formoterol,
flutiform
®) for the maintenance treatment of asthma in
patients whose symptoms are not adequately controlled
with an ICS plus an ‘as-needed’ inhaled short-acting b2-
agonist, as well as in patients whose asthma is already
controlled with both an ICS and a LABA. This phase 3
clinical study compared the efficacy and safety of flutica-
sone/formoterol with fluticasone/salmeterol in adult
patients with mild-to-moderate–severe, persistent
asthma.
Methods
Study design, setting and objectives
This was an open-label, randomized, active-controlled,
parallel-group, phase 3 study, conducted at 25 centres
across five European countries (Germany, Hungary,
Poland, Romania and the UK; clinicaltrials.gov identifier:
NCT00476073). The study was performed in accordance
with the Declaration of Helsinki and Good Clinical Prac-
tice guidelines, and approved by independent ethics com-
mittees in each of the participating countries (Germany,
Ethik-Kommission der Landesärztekammer Rheinland-
Pfalz; Hungary, Egészségügyi Tudományos Tanács Klinikai
Farmakológiai Etikai Bizottsága; Poland, Ethics Committee
Medical University in Bialystok; Romania, Academia de
Stiinte Medicale, Comisia Nationala de Etica pentru Stu-
diul Clinic al Medicamentului; UK, North West Research
Ethics Committee). Written informed consent was
obtained from all patients. The study was initiated (first
patient, first visit) on 23 April 2007 and was completed
(last patient, last visit) on 13 March 2008.
The study was designed to demonstrate non-inferiority
of fluticasone/formoterol compared with fluticasone/sal-
meterol in controlling mild-to-moderate–severe persistent
asthma in adult patients. The primary objective of the
study was to demonstrate non-inferiority of fluticasone/
formoterol to fluticasone/salmeterol based on mean pre-
dose forced expiratory volume in the first second (FEV1).
Secondary objectives of the study were to compare the
two treatments with regards to: discontinuations due to
lack of efficacy; time to onset of action (defined as ‘the
f i r s tt i m ep o i n tp o s t - d o s ea tw h i c ht h eF E V 1 value was
≥ 12% increased, compared with pre-dose’); peak expira-
tory flow rates (PEFRs) and other lung function para-
meters; amount of rescue medication use; asthma
symptom scores; sleep disturbance due to asthma; daily
oral or parenteral corticosteroid doses; asthma exacerba-
tions; patient assessments of study medication; Asthma
Quality of Life Questionnaire (AQLQ) scores; and
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included a screening phase of 4–10 days to evaluate elig-
ibility for participation. On completion of the screening
phase, patients were reassessed for eligibility and rando-
mized to receive study treatment.
Inclusion and exclusion criteria
Men and women (aged ≥ 18 years) with mild-to-moder-
ate–severe, persistent asthma for ≥ 6 months prior to
screening were included in the study. Patients were
required to demonstrate a FEV1 of ≥ 40% and ≤ 85% of
predicted normal values [17] during the screening phase
following appropriate withholding of asthma medications
(if applicable). Patients were also required to show reversi-
bility of ≥ 15% in FEV1 after salbutamol inhalation (two
actuations, 100 μg per actuation) in order to be eligible for
randomization. Only patients who could demonstrate cor-
rect inhaler technique were entered into the study.
Among the exclusion criteria were: life-threatening
asthma within the past year; hospitalization or emergency
department visit for asthma in the 4 weeks prior to screen-
ing; systemic corticosteroid use in the month prior to
screening; omalizumab use in the past 6 months; use of a
leukotriene receptor antagonist in the week before screen-
ing; a smoking history that was either recent (in the 12
months prior to screening) or equivalent to ≥ 10 pack-
years (e.g. at least 20 cigarettes/day for 10 years); signifi-
cant non-reversible active pulmonary disease; and clini-
cally significant respiratory tract infection in the 4 weeks
prior to screening. Also prohibited was recent use (in the
past week) of b-blocking agents, tricyclic antidepressants,
monoamine oxidase inhibitors, astemizole, quinidine-type
anti-arrhythmics or potent CYP3A4 inhibitors. Current
use of medications that would have an effect on broncho-
spasm and/or lung function was also a criterion for
exclusion.
Interventions and randomization
Patients were randomized 1:1 to one of two treatment
groups, with two dose options available within each
group. Eligible patients were assigned a unique randomi-
zation number selected sequentially from a randomiza-
tion list via an interactive voice randomization system. A
random permuted block design was used to obtain a 1:1
ratio. Patients randomized to receive fluticasone/formo-
terol were to take two actuations of 50/5 μg or 125/5 μg
every 12 hours (i.e. 100/10 μgo r2 5 0 / 1 0μgt w i c ed a i l y ) .
Patients randomized to receive fluticasone/salmeterol
were to take two actuations of 50/25 μg or 125/25 μg
every 12 hours (i.e. 100/50 μgo r2 5 0 / 5 0μgt w i c ed a i l y ) .
Both study treatments were administered via a hydro-
fluoroalkane pressurized metered-dose inhaler with an
AeroChamber
® Plus spacer device (GlaxoSmithKline,
Uxbridge, UK).
The starting dose of each medication was selected
based on each patient’s asthma history and pre-study
asthma medication. Patients who required ICSs at a dose
of 100–250 μg/day fluticasone or equivalent received the
low dose of study medication, while patients who
required > 250 μg/day (up to 1000 μg/day) fluticasone or
equivalent received the high dose of study medication.
Patients receiving the low dose of study medication were
permitted to switch to the high dose during the treat-
ment period if their asthma was not controlled, at the
investigator’s discretion. The use of salbutamol (two
actuations, 100 μg per actuation, up to four occasions per
day) was permitted as rescue medication.
Compliance
At weeks 2, 6 and 12 the approximate number of actua-
tions made since the previous visit was recorded. Compli-
ance was calculated as the number of actuations taken (i.e.
sum of values from weeks 2, 6 and 12) as a percentage of
the number of actuations that should have been taken (i.e.
number of study days multiplied by four).
Prior and concomitant medication
All concomitant medications and therapies that were
ongoing at the date of informed consent were recorded.
Efficacy assessments
During the 12-week treatment phase, patients under-
went lung function tests (forced vital capacity [FVC],
maximum expiratory flow at 25%, 50% and 75% of
volume to exhale [MEF25,M E F 50,M E F 75]a n dP E F R )a t
weeks 0 (baseline), 2, 6 and 12. Each of these tests was
performed in the 30 minutes prior to administration of
study medication and repeated 5, 10, 30, 60, 90 and 120
minutes post-treatment. PEFR measurements were
assessed for reproducibility by completing a minimum
of three acceptable manoeuvres (based on American
Thoracic Society/European Respiratory Society guide-
lines) with the two largest FEV1 measurements not vary-
ing by more than 0.15 L. The measurement with the
best FEV1 was selected for recording of PEFR. In addi-
tion, patients recorded their morning and evening peak
flow rates daily. Patients were also assessed for asthma
exacerbations (at weeks 2, 6 and 12), completed the
AQLQ [18] (at weeks 0 and 12) and performed an
assessment of their study medication at week 12 (5-
point scale ranging from very poor to very good). Mild-
to-moderate exacerbations were: pre-dose morning
PEFR > 30% below baseline on ≥ 2 consecutive days;
night awakening due to asthma ≥ 2 consecutive days; or
use of salbutamol rescue medication > 4 times per day
for ≥ 2 consecutive days. Severe exacerbations were
deterioration in asthma requiring additional therapy, or
emergency visit or hospitalization due to asthma. On a
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recorded the following information by means of an elec-
tronic diary: rescue medication use; asthma symptom
scores; sleep disturbance due to asthma; morning and
evening PEFR; and study medication taken.
Safety assessments
Safety assessments were made at weeks 2, 6 and 12 after
the start of treatment. Adverse events were documented
based on spontaneous reporting, patient interview and
diary entries. Clinical laboratory tests (haematology, bio-
chemistry and urinalysis) were performed at screening,
week 6 and week 12. Vital signs (blood pressure, heart
rate, respiration rate and oral temperature) were
assessed at screening and week 12. Twelve-lead electro-
cardiograms were recorded at screening, week 6 and
week 12. Patients were followed up by telephone 14
days after completion of/discontinuation from the study
to report any ongoing or new AEs.
Sample size
The sample size was focused on the difference in the
12-week FEV1 values analysed within a linear model
with the baseline FEV1 value as a covariate. It was
assumed that the observed treatment difference would
not exceed 0.02 and the stan d a r dd e v i a t i o nw o u l db e
0.5. The non-inferiority bound was fixed to 0.2, corre-
sponding to an effect size of 0.4, which could be inter-
preted as ‘mild-to-moderate’. For a two-sided level of
significance (a = 0.05, power of 80%), 113 patients per
treatment group were required. Assuming a correlation
between the 12-week and baseline FEV1 values of
approximately 0.5, the sample size would be reduced to
85 patients per treatment group. The comparison was
focused on the per protocol (PP) population. Assuming
that approximately 10% of the randomized patients
would not be part of the PP population, 200 patients
needed to be randomized to this study.
Analysis populations
The relevant study sets were as follows: safety popula-
tion, all patients who received study treatment and had
at least one post-dose safety assessment; full analysis set
(FAS), all randomized patients who received study treat-
ment and had at least one post-dose primary efficacy
(FEV1) measurement; PP population, all FAS patients
who completed the study without major protocol viola-
tions affecting the primary efficacy (FEV1) endpoint.
Statistical analyses
The primary endpoint (pre-dose FEV1 at week 12) and
several secondary efficacy endpoints (change from base-
line to week 12 in pre-dose FEV1, change from pre-dose
FEV1 at baseline to 2-hour post-dose FEV1 at week 12,
discontinuations due to lack of efficacy and time to
onset of action) were tested on the PP population in a
confirmatory manner, with pre-defined non-inferiority
limits. Non-inferiority for the primary endpoint would
be concluded if the lower limit of the 95% confidence
interval (CI) was ≥ –0.2 L. For discontinuation due to
lack of efficacy, the upper limit of the 95% CI was
required to be ≤ 10% (for the difference between the
percentage of patients in each treatment group) for
non-inferiority to be demonstrated.
Non-inferiority of fluticasone/formoterol to fluticasone/
salmeterol for the primary endpoint was tested on the PP
population using an analysis of covariance (ANCOVA)
with treatment and dose group as factors and the pre-dose
FEV1 values at week 0 as a linear covariate, and centre as a
random effect. Secondary endpoints were analysed as fol-
lows: change in pre- and post-dose FEV1, PEFR measure-
ments, other lung function parameters and AQLQ scores
were analysed using ANCOVA; the difference in percen-
tages and 95% CIs were calculated for discontinuations
due to lack of efficacy; time to onset of action was ana-
lysed using the multiple failures time model [19]; rescue
medication use was analysed using a Wilcoxon rank sum
test; asthma symptoms and sleep disturbance scores were
analysed using a linear model; patient assessment of
asthma medication was analysed using a proportional
odds model; asthma exacerbations were analysed using
Fisher’s exact test. Other endpoints, including safety para-
meters, were summarized using descriptive statistics. All
hypothesis tests were two-sided and conducted at the 5%
error level.
Results
Recruitment and patient flow
The study was initiated (first patient, first visit) on 23
April 2007 and was completed (last patient, last visit) on
13 March 2008. Of the 202 patients randomized (101
per treatment group), 189 (93.6%) completed the study
and 13 (6.4%) discontinued prematurely (Figure 1). Of
the 13 patients who did not complete the study, five
(2.5%) withdrew by choice (four in the fluticasone/for-
moterol group, one in the fluticasone/salmeterol group),
four (2.0%) were withdrawn due to lack of therapeutic
effect (two in each group), three (1.5%) were withdrawn
for administrative reasons (all in the fluticasone/salme-
terol group), and one (0.5%) was withdrawn due to an
AE (fluticasone/formoterol group). The safety popula-
tion, PP population and FAS comprised 202, 191 and
202 patients, respectively.
Baseline demographics and characteristics
The demographics and asthma characteristics of patients
in the fluticasone/formoterol and fluticasone/salmeterol
groups were similar (Table 1). There were no relevant
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Table 1 Demographic characteristics, asthma status and treatment at screening
Fluticasone/formoterol Fluticasone/salmeterol
(N = 101) (N = 101)
Age (years)
Mean ± SD 47.6 ± 12.6 46.0 ± 12.9
Median (range) 50.0 (18–75) 47.0 (18–76)
Gender
Male, n (%) 47 (46.5) 39 (38.6)
Female, n (%) 54 (53.5) 62 (61.4)
Race
Caucasian, n (%) 101 (100.0) 101 (100.0)
Weight (kg), mean ± SD 79.0 ± 15.3 76.1 ± 16.3
Height (cm), mean ± SD 170.2 ± 9.9 167.6 ± 8.4
BMI (kg/m
2), mean ± SD 27.3 ± 4.8 27.1 ± 5.3
FEV1 pre-salbutamol (L), mean ± SD 2.11 ± 0.56 2.11 ± 0.52
FEV1 post-salbutamol (L), mean ± SD 2.70 ± 0.79 2.63 ± 0.66
Predicted FEV1 (L), mean ± SD 3.20 ± 0.73 3.08 ± 0.65
FEV1 % predicted, mean ± SD (range) 66.1 ± 10.1 (41–85) 68.6 ± 9.2 (44–85)
FEV1 reversibility (%), mean ± SD 27.6 ± 12.8 24.9 ± 9.9
Treatment
ICS, n (%) 93 (92.1) 94 (93.1)
ICS dose (μg), median (range)* 500 (100–1000) 400 (100–1000)
LABA, n (%) 78 (77.2) 78 (77.2)
BMI, body mass index; FEV1, forced expiratory volume in the first second; SD, standard deviation; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist.
*Based on fluticasone equivalent, according to the GINA guideline on equipotency of ICS [20].
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demonstrated an FEV1 of ≥ 40% to ≤ 85% of predicted
normal values, as described in the inclusion criteria.
FEV1 reversibility ranged from 15% to 82% across the
two groups. Mean baseline AQLQ scores were 4.9 ± 1.0
in the fluticasone/formoterol group and 4.7 ± 1.0 in the
fluticasone/salmeterol group. Inhaled corticosteroid and
LABA use was similar in the two groups, as was ICS
dose (based on the Global Initiative for Asthma guide-
line on equipotency of ICS [20]).
Starting dose of study medication
A total of 73 (72.3%) patients in the fluticasone/formo-
terol group and 76 (75.2%) patients in the fluticasone/
salmeterol group started the study on the high-dose
option. Only a very small number of patients required a
change in dose strength (to a higher dose) during the
study (five in the fluticasone/formoterol group, three in
the fluticasone/salmeterol group).
Compliance
Compliance was over 75% in 99% of patients in the flu-
ticasone/formoterol group and in 98% of patients in the
fluticasone/salmeterol group.
Primary outcome measure
In terms of the primary efficacy endpoint, mean pre-
dose FEV1 at week 12, fluticasone/formoterol was com-
parable to fluticasone/salmeterol (least-squares [LS]
mean of the treatment difference at week 12: –0.061 L;
95% CI: –0.161, 0.040; p = 0.007, demonstrating non-
inferiority; PP population; Figure 2).
Secondary outcome measures
With regards to the secondary efficacy endpoints, fluti-
casone/formoterol was comparable to fluticasone/salme-
terol in terms of the change in pre-dose FEV1 from
baseline to week 12 (LS mean of the treatment differ-
ence: –0.061 L; 95% CI: –0.161, 0.040; p = 0.007; PP
population, Table 2). A supportive analysis, in the form
of an ANCOVA that included a treatment by dose
group (i.e. higher or lower dose) interaction, further
confirmed non-inferiority of fluticasone/formoterol for
this secondary parameter. Fluticasone/formoterol was
also comparable to fluticasone/salmeterol in terms of
t h ec h a n g ef r o mp r e - d o s eF E V 1 at baseline to 2-hour
post-dose FEV1 at week 12 (LS mean of the treatment
difference: –0.013 L; 95% CI: –0.129, 0.103; p =0 . 0 0 2 ;
PP population, Table 2).
In the PP population, fluticasone/formoterol was com-
parable to fluticasone/salmeterol in terms of disconti-
nuation due to lack of efficacy, which occurred once in
the fluticasone/formoterol group and twice in the fluti-
casone/salmeterol group. This translated to a difference
of –1.1% (95% CI: –4.6, 2.5), with non-inferiority of flu-
ticasone/formoterol to fluticasone/salmeterol duly
demonstrated for the PP population (because upper
limit of the CI was ≤ 10%).
Time to onset of action
Fluticasone/formoterol was superior to fluticasone/sal-
meterol with regards to the time to onset of action
throughout the 12 weeks of the study. Analysis of time
to onset of action using the multiple failures time model
showed superiority of fluticasone/formoterol over fluti-
casone/salmeterol (hazard ratio: 1.64; 95% CI: 1.28, 2.10;
p < 0.001; FAS; see Figure 3 as an example of this
effect). The proportion of patients in both treatment
groups showing onset of action (onset of action was
defined as the first time point post-dose at which FEV1
was at least 12% greater than the pre-dose value) at
weeks 2, 6 and 12 was lower than at week 0 (baseline),
but fluticasone/formoterol continued to have a faster
onset of action than fluticasone/salmeterol at all visits.
Other secondary outcome measures
Fluticasone/formoterol demonstrated similar efficacy to
fluticasone/salmeterol for other secondary parameters,
as summarized in Table 3. Mean (range) asthma symp-
t o ms c o r e si nt h ef i r s tw e e ko ft h es t u d yw e r e0 . 7 4( 0 –
3.29) and 0.58 (0–3.00) in the fluticasone/formoterol
and fluticasone/salmeterol groups, respectively. Corre-
sponding values in the last week of the study were 0.51
(0–3.14) and 0.39 (0–3.43). Changes from baseline in
various lung function tests are given in Table 4.
The percentage of patients assessing each medication
as good or very good was high in both groups (84% in
the fluticasone/formoterol group, 91% in the flutica-
sone/salmeterol group).
Figure 2 Mean (± 95% CI) pre-dose FEV1 throughout treatment.
Data shown for per protocol population. Least-squares mean of the
treatment difference at week 12: –0.061 L; 95% CI: –0.161, 0.040;
p = 0.007, demonstrating non-inferiority. CI, confidence interval; FEV1,
forced expiratory volume in the first second.
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The two treatment groups had similar safety and tolerabil-
ity profiles. The overall rate of AEs was 23.8% in both treat-
ment groups. The majority of AEs were of mild or
moderate intensity; severe AEs were experienced by two
patients in the fluticasone/formoterol group (2.0%). The
most common AEs in both groups were ‘infections and
infestations’, occurring in 13.9% of patients in the
fluticasone/formoterol group and 12.9% of patients in the
fluticasone/salmeterol group. AEs judged to be related to
treatment were documented for one patient in each treat-
ment group. Serious AEs (SAEs) were also reported for one
patient in each treatment group. The SAEs experienced by
the patient in the fluticasone/formoterol group (haemor-
rhagic stroke and cardiac arrest, approximately 2 months
after randomization) led to withdrawal from the study, and
had a fatal outcome. The SAE reported in the fluticasone/
salmeterol group was pneumococcal pneumonia. All SAEs
were considered unrelated to treatment with study medica-
tion by both the investigators and the sponsor.
There were no noteworthy changes in laboratory para-
meters, vital signs or electrocardiograms. No systemic
effects of LABAs were observed (e.g. elevation of serum
glucose or reduced serum potassium concentrations).
Discussion
The efficacy of inhaled fluticasone and of inhaled formo-
terol is documented extensively in the literature, includ-
ing as part of ICS/LABA combination therapies with
other components [15,21-26]. Prescribing data indicate
that fluticasone and formoterol are already co-prescribed
and used concurrently in patients with asthma. Now
these two components are brought together into a single
combination therapy option. It has previously been
demonstrated that fluticasone/formoterol has compar-
able efficacy to its individual components administered
concurrently [27].
This study demonstrated that fluticasone/formoterol is
comparable to standard fluticasone/salmeterol therapy
in terms of the primary endpoint (pre-dose FEV1 at
week 12), as well as for several secondary efficacy end-
points (change from baseline to week 12 in pre-dose
FEV1,c h a n g ef r o mp r e - d o s eF E V 1 at baseline to 2-hour
post-dose FEV1 at week 12 and discontinuation due to
lack of efficacy). Fluticasone/formoterol also demon-
strated similar efficacy to fluticasone/salmeterol for var-
ious other measures of lung function, rescue medication
use, patient reported outcomes and asthma exacerba-
tions. Furthermore, the safety and tolerability profiles of
the two treatments were similar.
Figure 3 Time to onset of action of study medication at
baseline (day 0; similar plots were obtained at weeks 2, 6 and
12). Data based on Kaplan-Meier survival analysis (full analysis set).
Onset of action was defined as the first time point post-dose at
which FEV1 was at least 12% greater than the pre-dose value.
Analysis of time to onset of action using the multiple failures time
model showed superiority of fluticasone/formoterol over
fluticasone/salmeterol (hazard ratio: 1.64; 95% CI: 1.28, 2.10;
p < 0.001). On day 0, more than twice as many patients had a
bronchodilatory response that met the onset of action criterion in
the fluticasone/formoterol group than in the fluticasone/salmeterol
group at 5 minutes post-dose (39% versus 14%, respectively). In
addition, a larger proportion of patients in the fluticasone/
formoterol group met the onset of action criteria within 2 hours
(post-dose), than in the fluticasone/salmeterol group (77% versus
64%, respectively; day 0). This trend continued over the 12-week
treatment period, with consistently more patients achieving the
predefined onset of action response in the fluticasone/formoterol
group than in the fluticasone/salmeterol group at each post-dose
time point (5–120 minutes). CI, confidence interval; FEV1, forced
expiratory volume in the first second.
Table 2 Change in FEV1 assessments from baseline to week 12
Parameter Change from baseline (L)
LS mean (95% CI)
Difference between groups (L)




Fluticasone/formoterol 0.196 (0.117, 0.275) –0.061 (–0.161, 0.040) 0.007
Fluticasone/salmeterol 0.257 (0.177, 0.336)
Post-dose FEV1
Fluticasone/formoterol 0.464 (0.374, 0.555) –0.013 (–0.129, 0.103) 0.002
Fluticasone/salmeterol 0.477 (0.384, 0.569)
FEV1, forced expiratory volume in the first second; LS, least-squares mean.
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Difference Fluticasone/formoterol – fluticasone/
salmeterol
Discontinuations due to lack of efficacy (%) PP % –1.1
95% CI
a,b –4.6, 2.5*
Time to onset of action of study medication
(minutes)
FAS Hazard ratio 1.64
95% CI 1.28, 2.10
p value < 0.001*
Rescue medication use (% of study days) FAS HL estimate 2.24
95% CI –0.03, 7.06
p value 0.157
Rescue medication use (number of uses) FAS HL estimate 0.02
95% CI 0.00, 0.11
p value 0.164
Pre-dose PEFR at week 12 (L/min) FAS LS mean –13.6
95% CI –34.9, 7.6
p value 0.208
2-hour post-dose PEFR at week 12 (L/min) FAS LS mean –10.0
95% CI –33.6, 13.7
p value 0.408
Other lung function parameters (FVC, MEF25, MEF50
and MEF75)




Asthma symptom scores (mean values) FAS Mean
c 0.15
95% CI –0.04, 0.34
p value 0.122
Sleep disturbance scores (mean values) FAS Mean
c 0.00
95% CI –0.12, 0.11
p value 0.975
Asthma exacerbations: mild/moderate FAS n (%) Fluticasone/formoterol: 11 (10.9)
Fluticasone/salmeterol: 12 (11.9)
p value > 0.999
Asthma exacerbations: severe FAS n (%) Fluticasone/formoterol: 3 (3.0)
Fluticasone/salmeterol: 1 (1.0)
p value 0.621
Patient assessment of study medication (scores at
week 12)
FAS Odds ratio 0.495
95% CI
c 0.289, 0.848
AQLQ (scores at week 12) FAS Mean (SD) Fluticasone/formoterol: 5.4 (1.1)
Fluticasone/salmeterol: 5.5 (0.9)
p value 0.051
*Statistically significant non-inferiority (discontinuations due to lack of efficacy) or superiority (time to onset of action) of fluticasone/formoterol versus
fluticasone/salmeterol based on sequential gatekeeping approach.
aNon-inferiority of fluticasone/formoterol to fluticasone/salmeterol is shown if the upper limit of the 95% CI is ≤ 10%.
bp value not calculated.
cAdjusted mean from linear model on mean score with treatment group as factor.
AQLQ, Asthma Quality of Life Questionnaire; CI, confidence interval; FAS, full analysis set; FVC, forced vital capacity; HL, Hodges Lehmann; LS, least-squares;
MEF25;M E F 50; MEF75, maximum expiratory flow rate at, respectively, 25%; 50%; and 75% of the volume to exhale; PEFR, peak expiratory flow rate; PP, per
protocol population; SD, standard deviation.
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fluticasone/salmeterol in terms of time to onset of
action. This is most likely to be due to the rapid onset
of action of formoterol, which is equivalent to that of
salbutamol [16]. Although the proportion of patients in
both treatment groups showing onset of action at weeks
2, 6 and 12 was lower than at week 0 (baseline), reflect-
ing the fact that the patients were not as well controlled
at baseline and thus more responsive to study medica-
tion, the superiority of fluticasone/formoterol over fluti-
casone/salmeterol was maintained. The benefit of
fluticasone/formoterol in terms of speed of onset of
action may be clinically important, given that a consen-
sus panel of practising physicians has suggested that a
rapid onset of action might be expected to have a posi-
tive impact on the adherence of patients to their treat-
ment [28]. However, it should also be considered that
patients who are well controlled may not experience the
benefit offered by a medication with a rapid onset of
action.
A potential limitation of any randomized clinical trial
is the extent to which it reflects real-life practice, parti-
cularly bearing in mind the discrepancies between treat-
ment efficacy in controlled trials and the levels of
asthma control observed in clinical practice. Clearly,
randomized, controlled trials have an important role,
but more pragmatic assessments of ‘real-world effective-
ness’ may complement these data, particularly given the
relevance of patient preference and adherence in this
field [29]. For example, the odds ratio for the overall
patient assessment of study medication for fluticasone/
formoterol compared with fluticasone/salmeterol was in
favour of the latter. Nevertheless, the study medication
was assessed as good or very good by 84% of patients in
the fluticasone/formoterol group and 91% of those in
the fluticasone/salmeterol group. This needs to be con-
sidered in the context of a tightly regulated trial setting
with good levels of compliance. In real-life practice,
where patients adopt self-management strategies and
often do not take their medication according to the
prescribed regimens, factors such as the speed at which
relief is perceived by the patient could have more
impact [28,30]. Trials aimed at assessing how different
treatments influence individual patients’ decision-mak-
ing need to be carefully designed in order to ensure
their relevance to practice [31].
In theory, patients may have been overtreated at base-
line and during the study, which could mask any differ-
ences between the two treatments. However, lung
function parameters, AQLQ scores and asthma symp-
tom scores improved (at least numerically) from base-
line in both groups (AQLQ data not shown) suggesting
that patients were not overtreated. Nevertheless, in
hindsight it may have been useful to have used a stan-
dardized asthma control questionnaire throughout the
study to provide insights into control at baseline.
It is worth noting that this study was open-label in
design. It was not deemed likely, however, that the non-
blinded nature of this study had a detrimental effect on
the results, because the primary efficacy measure was a
physical rather than a subjective endpoint and analysis
of the data was blinded until its completion.
Conclusions
In conclusion, this study has demonstrated that flutica-
sone/formoterol has comparable efficacy to fluticasone/
salmeterol for patients with mild-to-moderate–severe,
persistent asthma, with regards to mean pre-dose FEV1
at week 12, change from baseline to week 12 in pre-
dose FEV1, change from pre-dose FEV1 at baseline to
post-dose FEV1 at week 12 and discontinuation due to
lack of efficacy. Superiority of fluticasone/formoterol
over fluticasone/salmeterol was shown for time to onset
of action of study medication over the 12 weeks of the
study. Analysis of additional efficacy parameters such as
other lung function tests, patient-reported outcomes,
rescue medication use, asthma exacerbations and AQLQ
scores yielded comparable results for the two treatment
groups. Furthermore, fluticasone/formoterol was well
tolerated with a good safety profile.
These data suggest that the fluticasone/formoterol
combination will offer patients a treatment option that
is as effective as fluticasone/salmeterol, but with a more
rapid onset of action. There is therefore potential for
the new combination to have a positive impact on
adherence to treatment, and hence on asthma outcomes.
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